Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606957 | 0.98 | KMO (0.33) | KMOL3MBTL1HRH4 | |
| SCHEMBL314963 | 0.94 | — | — | |
| SCHEMBL1608271 | 0.72 | — | — | |
| SCHEMBL3290525 | 0.71 | — | — | |
| SCHEMBL9446205 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL5607760 | 0.68 | — | — | |
| SCHEMBL8562907 | 0.67 | HRH4 (0.36) | HRH4 | |
| SCHEMBL12495114 | 0.67 | — | — | |
| SCHEMBL738431 | 0.64 | PDE4A (0.31) | — | |
| SCHEMBL9220164 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-12-07 | — | — | US | claimed |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. | 2021-03-25 | — | — | US | claimed |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-10-29 | — | — | US | claimed |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2018-09-20 | — | — | US | claimed |
| US-9987259-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-06-05 | — | — | US | claimed |
| EP-2592072-B1 | Human protein tyrosine phosphatase inhibitors and their use | AERPIO THERAPEUTICS INC (US) | 2017-09-20 | — | — | EP | claimed |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-06-16 | — | — | US | claimed |
| US-9271976-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | claimed |
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOBPHARMACEUTICALS CO LTD (KR) | 2015-04-23 | — | — | US | claimed |
| US-8952165-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-02-10 | — | — | US | claimed |
| US-20130296340-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-11-07 | — | — | US | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-0821675-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033176-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0478974-B1 | N-Heteroaryl-2-nitroanilines | BASF AG (DE) | 1995-12-27 | — | — | EP | disclosed |
| US-5298515-A | N-hetaryl-2-nitroanilines | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0478974-A1 | N-Heteroaryl-2-nitroanilines | BASF Aktiengesellschaft (DE) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | KMO 4770/4885L3MBTL1 3001/4885CTSK 1825/4885 |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | KMO 3669/4885L3MBTL1 4141/4885CTSK 2340/4885 |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | KMO 3669/4885L3MBTL1 4141/4885CTSK 2340/4885 |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-20130296340-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | PLPBP, PDXK, PIR | KMO 153/4885L3MBTL1 4738/4885CTSK 1758/4885 |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PNPO | KMO 165/4885L3MBTL1 4681/4885CTSK 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.